This is ‘the most important decision’ the FDA will make in 2020, says analyst
The Food and Drug Administration‘s call on whether to approve Biogen‘s experimental Alzheimer’s drug, aducanumab, will be the “most important decision” the federal regulator will make in 2020, Bernstein analyst Ronny Gal said Friday. When asked if he thought the FDA would approve the drug, Gal said, “Yes.” “[But] you’ve got to be cautious about… Read More »
